BioSyent is firing on all cylinders, says Cantor Fitzgerald Canada

Biosyent's leading brand is FeraMAX. It currently markets two formulations for the treatment of iron deficient anemia.

Another strong quarter has Cantor Fitzgerald Canada analyst Scott Curtis feeling bullish about BioSyent (TSXV:RX). On Wednesday, BioSyent reported its Q1, 2015 results. The company earned $962,712 on sales of $3.30-million, a 35% increase over last year’s first quarter. “Our first quarter results were powered by our Canadian pharma business,” said CEO Rene Goehrum. “In […]

Tribute Pharmaceuticals gets price target raise at Laurentian

Tribute Pharmaceuticals CEO Rob Harris.

The continuation of strong growth at Tribute Pharmaceuticals (TSXV:TRX) has earned the company a price target raise from Laurentian Bank Securities analyst Joseph Walewicz. Yesterday, Tribute reported its Q1, 2015 results. The company lost $5.18-million on revenue of $5.59-million, a topline that was up 60% over last year’s first quarter. “These solid results culminate the […]

FusionPipe Collaborates With UBC Students On Wearable Health Application for Thalmic Labs Myo


Vancouver password-less authentication systems developer FusionPipe has developed an application for Thalmic Labs’ Myo armband in a six-month collaboration with students from UBC’s Electrical Engineering and Computer Engineering department that provides a hands-free method for physicians and healthcare professionals to use mobile devices without touching them. Using a Myo armband in the healthcare workspace provides […]

Merus Labs financing gets thumbs up at Laurentian


Merus Labs’ (TSX:MSL, Nasdaq:MSLI) bought deal will put the company in a position to execute on acquisitions, says Laurentian Bank Securities analyst Joseph Walewicz. Yesterday, Merus Labs announced it had close a previously announced bought-deal financing. Merus issued 19,672,200 common shares at a price of $3.05 per share for gross proceeds of $60,000,210. A greenshoe […]

Belle Gibson’s Fake Cancer Admission the Latest Blow to Homeopathic Quackery


In a mea culpa to be published in Australian Women’s Weekly tomorrow, foodie “wellness” blogger and terminal brain cancer survivor Belle Gibson admits that she made the whole thing up, in an article pungently titled “The Girl Who Conned Us All”. Asked directly if she had ever had cancer, a narrative gobbled up by a […]

Theratechnologies gets soft response to Q1 results

Shares of the Theratechnologies fell in half last June when Ferrer announced it would withdraw the marketing authorization application with the European Medicines Agency for Egrifta, the company's tesamorelin application proposed for the treatment of excess abdominal fat in HIV patients with lipodystrophy.

Shares of Theratechnologies (TSX:TH) are down slightly today after the company reported its Q1, 2015 results. In the quarter, the company lost $914,000 on revenue of $4.56-million, up 72% from Q4’s topline and a significant bump over last year’s Q1 revenue number of $1.67-million. “As first-quarter results demonstrate, Theratechnologies is executing its business plan well,” […]

Patient Home Monitoring increases financing to $58.5-million

Patient Home Monitoring says it intends to benefit from the trends of an aging population and a push by U.S. Medicare to reduce costs by encouraging in-home healthcare services.

High flying healthcare player Patient Home Monitoring (TSXV:PHM) has upped its previously announced financing. The company, which has seen its shares more than quadruple since last fall, says it will now raise $58.5-million in a bought deal led by Mackie Research Capital with a syndicate that is comprised of GMP and Beacon. The company will […]

How Technology Can Protect Consumers and Pharma Companies From Fake Drugs


This report was adapted by Cantech Letter from a piece prepared by Sophic Capital. For the original report, and more in-depth research, please visit Sophic Capital’s website, here. The counterfeit pharmaceutical industry could be worth as much as $200 billion annually, which is slightly less than the $246 billion illicit drug trade. Criminal organizations are […]

Buy BioSyent on weakness, says Cantor Fitzgerald Canada

Biosyent's leading brand is FeraMAX. It currently markets two formulations for the treatment of iron deficient anemia.

The current weakness in shares of BioSysent (TSXV:RX) is a buying opportunity, says Cantor Fitzgerald Canada analyst Scott Curtis. In a research update to clients yesterday, Curtis reiterated his “Speculative Buy” rating and $13.25 one-year target on BioSyent, implying a return of 58% at the time of publication. Curtis says despite recent nervousness in the […]

Is radioactivity from Fukushima dangerous to British Columbians?

Woods Hole Oceanographic Institution  marine radiochemist Ken Buesseler in front of the Fukushima Dai-ichi nuclear plant. (Photo courtesy Ken Buesseler)

After calling on the public to help gather samples, scientists at the Massachusetts-based Woods Hole Oceanographic Institution says traces of radioactivity from the meltdown 2011 meltdown of Japan’s Fukushima Daiichi nuclear plan are showing up in B.C. waters. But researchers says there is good news: the levels of radioactivity likely pose no threat. “Radioactivity can […]